PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

August 31, 2016

Conditions
Atherosclerotic DiseasePerioperative Bleeding
Interventions
DRUG

Tranexamic Acid

DRUG

Tranexamic Acid Placebo

DRUG

Rosuvastatin or matching placebo

Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.

Trial Locations (2)

L8L 2X2

Hamilton General Hospital, Hamilton

L8V 1C3

Juravinski Hospital, Hamilton

Sponsors
All Listed Sponsors
collaborator

Population Health Research Institute

OTHER

collaborator

Hamilton Health Sciences Corporation

OTHER

lead

McMaster University

OTHER

NCT02546648 - PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study | Biotech Hunter | Biotech Hunter